ATE470862T1 - Vorrichtung und verfahren zur unterscheidung zwischen akuter und chronischer myokardial- nekrose bei symptomatischen patienten - Google Patents

Vorrichtung und verfahren zur unterscheidung zwischen akuter und chronischer myokardial- nekrose bei symptomatischen patienten

Info

Publication number
ATE470862T1
ATE470862T1 AT06111716T AT06111716T ATE470862T1 AT E470862 T1 ATE470862 T1 AT E470862T1 AT 06111716 T AT06111716 T AT 06111716T AT 06111716 T AT06111716 T AT 06111716T AT E470862 T1 ATE470862 T1 AT E470862T1
Authority
AT
Austria
Prior art keywords
acute
sample
subject
determining
amount
Prior art date
Application number
AT06111716T
Other languages
English (en)
Inventor
Georg Hess
Andrea Horsch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE470862T1 publication Critical patent/ATE470862T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
AT06111716T 2006-03-24 2006-03-24 Vorrichtung und verfahren zur unterscheidung zwischen akuter und chronischer myokardial- nekrose bei symptomatischen patienten ATE470862T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06111716A EP1837659B1 (de) 2006-03-24 2006-03-24 Vorrichtung und Verfahren zur Unterscheidung zwischen akuter und chronischer Myokardial-Nekrose bei symptomatischen Patienten

Publications (1)

Publication Number Publication Date
ATE470862T1 true ATE470862T1 (de) 2010-06-15

Family

ID=36129718

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06111716T ATE470862T1 (de) 2006-03-24 2006-03-24 Vorrichtung und verfahren zur unterscheidung zwischen akuter und chronischer myokardial- nekrose bei symptomatischen patienten

Country Status (9)

Country Link
US (1) US7732214B2 (de)
EP (2) EP1837659B1 (de)
JP (1) JP4944185B2 (de)
CN (1) CN101410716A (de)
AT (1) ATE470862T1 (de)
CA (1) CA2646245A1 (de)
DE (1) DE602006014798D1 (de)
ES (1) ES2344993T3 (de)
WO (1) WO2007110359A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1890154B1 (de) * 2006-08-16 2012-07-04 F. Hoffmann-La Roche AG Herztroponin als Indikator für fortgeschrittene Koronararterienerkrankung und deren Komplikationen
JP2011501113A (ja) * 2007-10-10 2011-01-06 エフ．ホフマン−ラ ロシュ アーゲー 急性冠症候群を有する患者での既存の心筋機能不全の評価のためのナトリウム利尿ペプチド／トロポニン比
EP2324358A1 (de) * 2008-07-23 2011-05-25 F. Hoffmann-La Roche AG Überwachung einer antiangiogenesetherapie
JP5528461B2 (ja) * 2008-10-17 2014-06-25 エフ．ホフマン−ラ ロシュ アーゲー 心不全の評価におけるビグリカンの使用
WO2011012268A1 (en) * 2009-07-27 2011-02-03 Roche Diagnostics Gmbh Use of mimecan in the assessment of heart failure
EP2499489B1 (de) * 2009-11-13 2015-01-07 BG Medicine, Inc. Risikofaktoren und vorhersage von myokardinfarkt
ES2647461T3 (es) * 2009-12-18 2017-12-21 F. Hoffmann-La Roche Ag GDF-15 y/o troponina T para predecir insuficiencia renal en pacientes con cirugía cardíaca
US20110306148A1 (en) 2010-06-14 2011-12-15 Siemens Healthcare Diagnostics Inc. Composition for use as an assay reagent
JP6059735B2 (ja) 2011-12-01 2017-01-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脳卒中診断のためのＮＴ−ｐｒｏＡＮＰ及びＮＴ−ｐｒｏＢＮＰ
KR101531835B1 (ko) * 2013-10-16 2015-06-29 한국표준과학연구원 화학적 동위원소 치환법을 이용한 혈액 내 뇌성 나트륨 이뇨 펩타이드 질량분석법
US20200264196A1 (en) * 2017-09-30 2020-08-20 Alfred Health Method of prognosis
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
EP1322957B1 (de) * 2001-05-04 2009-08-12 Biosite Incorporated Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
US6461828B1 (en) * 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure
US7109023B2 (en) * 2002-11-18 2006-09-19 Princeton Biomeditech Corporation Immunossay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients
CA2511269A1 (en) * 2004-07-07 2006-01-07 F. Hoffmann-La Roche Ag Multimarker panel based on p1gf for diabetes type 1 and 2
EP1731910A1 (de) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Gebrauch von NT-proANP und NT-proBNP für die Diagnose von Herzkrankheiten

Also Published As

Publication number Publication date
DE602006014798D1 (de) 2010-07-22
US20090087918A1 (en) 2009-04-02
EP1837659B1 (de) 2010-06-09
JP4944185B2 (ja) 2012-05-30
WO2007110359A1 (en) 2007-10-04
JP2009536726A (ja) 2009-10-15
ES2344993T3 (es) 2010-09-13
US7732214B2 (en) 2010-06-08
EP1999475A1 (de) 2008-12-10
CN101410716A (zh) 2009-04-15
CA2646245A1 (en) 2007-10-04
EP1837659A1 (de) 2007-09-26

Similar Documents

Publication Publication Date Title
ATE470862T1 (de) Vorrichtung und verfahren zur unterscheidung zwischen akuter und chronischer myokardial- nekrose bei symptomatischen patienten
EP2315034A3 (de) Mittel und Verfahren zur Risikobewertung von Herzeingriffen auf GDF-15-Basis
ATE452343T1 (de) Verbesserte vitamin-d-messung
ATE493649T1 (de) Verfahren zur diagnose von polyzystischer nierenkrankheit
GB0514435D0 (en) Diagnostic method for brain damage-related disorders
MY149843A (en) Method for quantifying reservoir connectivity using fluid travel times
WO2009047283A3 (en) Means and methods for monitoring myocardial infarction and its treatment
DE602006015281D1 (de) Verfahren und testvorrichtungen zur unterscheidung verschiedener formen von krankheiten und leiden, die durch thrombocytopenia und/oder durch spontane interaktionen zwischen dem von-willebrand-faktor und plättchen gekennzeichnet sind
EP3413052A3 (de) Igfbp7 zur diagnose von diastolischer dysfunktion
WO2005071407A3 (en) Methods of diagnosing acute coronary syndrome by measuring urotensin ii
WO2009104974A3 (en) Biomarkers for acute coronary disorder
ATE519116T1 (de) Verfahren zur normierung der konzentration von analyten in einer urinprobe
WO2011012268A8 (en) Use of mimecan in the assessment of heart failure
WO2006124456A3 (en) Competitive particle immunoassay methods utilizing fluorescence microscopy
DE602006010705D1 (de) Biochemische Marker für akute Lungenembolie
WO2006053251A3 (en) Method of measuring amyloid-beta peptides
DK1664793T3 (da) Neurotoksisk aminosyre eller neurotoksisk derivat deraf forbundet med neurologiske lidelser
DE602004029594D1 (de) Verfahren zur unterscheidung zwischen ischämischem und hämorrhagischem schlaganfall
ATE473448T1 (de) Verfahren zur diagnose von herz-kreislauf- krankheiten
WO2007079301A3 (en) Method of diagnosing a body weight condition or predisposition in an animal
WO2006066917A3 (en) Use of asc as a marker for colorectal cancer
WO2008061978A3 (en) Means and methods for optimization of diagnostic and therapeutic approaches in chronic artery disease based on the detection of troponin t and nt-probnp
MX2012002797A (es) Panel multimarcador para hipertrofia ventricular izquierda.
WO2009150181A3 (en) H-fabp as a marker for myocardial hibernation
ATE515574T1 (de) Verwendung von spla2-aktivität zur diagnose von herz-kreislauf-ereignissen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1837659

Country of ref document: EP